Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Recruiting

Phase 2

GSK-3 InhibitionTargeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Sponsor:

Hamilton Health Sciences Corporation

Code:

NCT06174220

Conditions

Arrhythmogenic Cardiomyopathy

Arrhythmogenic Right Ventricular Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tideglusib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-02. This information was provided to ClinicalTrials.gov by Hamilton Health Sciences Corporation on 2025-04-03.